CARISTI, Nicola
 Distribuzione geografica
Continente #
NA - Nord America 1.393
EU - Europa 1.104
AS - Asia 213
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 2.715
Nazione #
US - Stati Uniti d'America 1.392
SE - Svezia 348
IE - Irlanda 322
CN - Cina 193
UA - Ucraina 132
DE - Germania 89
FI - Finlandia 50
GB - Regno Unito 38
IT - Italia 36
AT - Austria 35
FR - Francia 31
BE - Belgio 12
IN - India 10
IR - Iran 7
RU - Federazione Russa 3
CH - Svizzera 2
EU - Europa 2
NZ - Nuova Zelanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
CA - Canada 1
ES - Italia 1
JP - Giappone 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
MM - Myanmar 1
NO - Norvegia 1
VN - Vietnam 1
Totale 2.715
Città #
Dublin 321
Chandler 300
Jacksonville 269
Nyköping 174
Beijing 86
Ashburn 80
Dearborn 67
Ann Arbor 55
Cambridge 49
Princeton 49
Medford 44
New York 44
Boardman 42
Des Moines 35
Vienna 35
Woodbridge 26
Jinan 21
Hebei 14
Lancaster 14
Wilmington 14
San Mateo 13
Brussels 12
Shenyang 11
Grammichele 8
Leawood 7
Nanjing 7
Pune 7
Zhengzhou 7
Norwalk 6
Tianjin 6
Ardabil 5
Haikou 5
Lanzhou 5
Washington 5
Jiaxing 4
Seattle 4
Augusta 3
Hangzhou 3
Los Angeles 3
Messina 3
Nanchang 3
Auckland 2
Changsha 2
Falls Church 2
Fuzhou 2
Guangzhou 2
Ningbo 2
Taiyuan 2
Taizhou 2
Clearwater 1
Columbus 1
Concorezzo 1
Edinburgh 1
Hanoi 1
Hefei 1
Hendon 1
Hillsdale 1
Houston 1
Kemerovo 1
Lappeenranta 1
Madrid 1
Malfa 1
Monmouth Junction 1
Mumbai 1
Nay Pyi Taw 1
Novokuznetsk 1
Philadelphia 1
Quartu Sant'elena 1
Ratoath 1
Sabz 1
Santa Clara 1
Setagaya-ku 1
Sezze 1
Staten Island 1
Stephentown 1
Wenzhou 1
Zurich 1
Ürümqi 1
Šiauliai 1
Totale 1.912
Nome #
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 80
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 77
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 75
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 74
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 73
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 73
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 73
Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? 71
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 70
Lactoferrin expression in colorectal cancer: relationships with proliferation indices and survival. 70
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 68
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 67
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 66
Phase II study paclitaxel (PTX) and cisplatin (Cis) in advanced and recurrent head&neck cancer 65
A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: A safety study 64
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 64
Influence of 5-fluorouracil and folinic acid on interleukin-18 production in colorectal cancer patients 63
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 61
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 60
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 60
Linfomi maligni: revisione epidemiologica di 150 casi 59
The treatment of recurrent and metastatic cervical carcinoma. Evaluation of an antiblastic combination of methotrexate-adriamycin-bleomycin (MAB) 59
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 58
ACUTE MEGAKARYOBLASTIC LEUKEMIA IN A CHILD 58
Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study 57
Behavior of serum sialic acid levels at various stages of neoplastic disease 54
Venous damage prevention by defibrotide in vinorelbine-treated patients 51
ONDANSETRON PLUS DEXAMETHASONE IN THE CONTROL OF HIGH-DOSE CISPLATIN-INDUCED EMESIS 50
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 50
Cisapride and dexamethasone in the prevention of delayed emesis after cisplatin administration 50
Oral vinorelbine as first-line chemoptherapy in elderly patients with hormone-refractory prostate cancer. 50
Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy 48
Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. 48
Oral vinorelbine as first line chemotherapy in unfit elderly patients with hormone-refractory prostate cancer 47
Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: Results of a pilot study 46
The treatment of recurrent and metastatic cervical carcinoma. Evaluation of anantiblastic combination of methotrexate-adriamycin-bleomycin (MAB). 45
Emerging targeted therapies for castration-resistant prostate cancer 45
Proceedings of the International Workshop on Scattering Studies of Mesoscopic Scale Structure and Dynamics in Soft Matter, held in Messina, Italy, 22-25 November 2000 - In honor of Professor Sow-Hsin Chen on the occasion of his 65th birthday - Preface 44
Raltitrexed and oxaliplatin as first line treatment of advanced pleural mesothelioma. Preliminary data of a phase II study. 44
POLIMORPHISM OF METHYLENE-TETRAHYDROFOLATE REDUCTASE AND RISK OF LUNG AND COLON-RECTAL CANCER: A CASE CONTROL STUDY 42
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 negative lymphnodes. 42
Palliative treatment of rectosigmoid tumors by endoscopic electrocoagulation 41
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 41
null 37
null 33
Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreatedmetastatic breast cancer. A multicenter phase II study 32
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 29
Protective effect of leuprolide on ovarian function in young women treated with adjuvant chemotherapy for early breast cancer: a multicenter phase II study. 28
Mitomycin c and capecitabine combination (MiXe) in heavily pretreated metastatic breast cancer patients. A dose-finding study 27
Transdermal fentanyl and pain control in neoplastic patients: our experience 26
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 19
Totale 2.734
Categoria #
all - tutte 9.016
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.016


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195 0 0 0 0 0 0 0 0 0 0 0 5
2019/2020472 75 31 5 29 4 63 67 56 7 58 74 3
2020/2021371 50 0 89 23 9 48 3 30 1 40 55 23
2021/2022353 5 62 9 8 12 3 15 11 7 75 41 105
2022/20231.055 77 110 40 97 89 112 25 71 389 3 29 13
2023/2024223 20 28 13 28 19 88 11 13 0 3 0 0
Totale 2.734